The overexpression of HER2 has been identified in multiple cancers including breast, gastric, urothelial, and colorectal cancer [2–5], and has also been recognized to be correlated with metastasis and poor prognosis of these tumors [6, 7]. This evidence concerns the gene ERBB2 and cancer.